Strides Pharma Science arm gets USFDA nod for pain relieving drug
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Children's Motrin Oral Suspension, 100 mg/mL, of Johnson Johnson Consumer Inc.
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Ibuprofen OTC Oral Suspension Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 19, 2021 for Pronomz Ventures LLP Strides Pharma gains 3 per cent on FDA approval for Prednisone Tablets
The product will be manufactured at Bengaluru facility Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our intimation letter dated February 10, 2021 and in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisements regarding completion of dispatch of Notice of Postal Ballot dated February 04, 2021, published in Business Standard (English - Edition) and in Lokmat (Marathi Edition). A copy of the said advertisement is also hosted on the Company's website at www.strides.com This is for your information and records. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Prednisone Tablets Strides Pharma Science Ltd - 532531 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot seeking approval of Members of the Company for 'Reclassification of SeQuent Scientific Limited from 'Promoter Group' to 'Public' category. Strides Pharma to pursue portfolio maximisation in regulated markets
To develop products across multiple therapeutics segments Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificates Kusuma Kumari Yerramilli
Strides Pharma in advanced talks for Covid-19 vaccine manufacturing deal
Once a deal is inked, the Covid-19 vaccine, developed by a global vaccine maker, will be manufactured by Strides' biotech subsidiary Stelis Biopharma